Companies › IMVT
IMMUNOVANT INC (IMVT)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001764013 · EDGAR filings · Updated 2026-07-24
IMMUNOVANT INC (IMVT) has reported institutional ownership of 53.9%, with 216 institutional managers holding positions valued at $2.75B per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.
Filings this week (6)
- 2026-07-24 — Insider transaction reported (Form 4)
- 2026-07-24 — Insider transaction reported (Form 4)
- 2026-07-24 — Insider transaction reported (Form 4)
- 2026-07-22 — ARS filed
- 2026-07-22 — DEFA14A filed
- 2026-07-22 — Proxy statement (DEF 14A) filed
Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, IMMUNOVANT INC has 216 institutional holders and institutional ownership of 53.9%.
Insider activity
Insiders reported 47 transactions (1 buys, 32 sells) across 15 reporting insiders, with a net reported value of $347.1M.
Data flags from SEC filings
Related companies
VERACYTE INC (VCYT) · DENALI THERAPEUTICS INC (DNLI) · CARIS LIFE SCIENCES INC (CAI) · DISC MEDICINE INC (IRON) · HAEMONETICS CORP MASS (HAE) · 10X GENOMICS INC (TXG)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-24.